Carcinoma of the Gallbladder ✅

Related Subjects: |Upper Gastrointestinal Bleed |Oesophageal Variceal Bleeding |Dieulafoy Lesion |Mallory-Weiss Tear |Gastric Cancer |Peptic Ulcer Disease |Hypovolaemic or Haemorrhagic Shock |Carcinoma of the Gallbladder |Carcinoma of the Bile Duct

🫙 Gallbladder carcinoma is a rare but aggressive biliary tract malignancy, often diagnosed late because early symptoms are vague. ⚠️ In UK practice, suspected cases should be discussed through a specialist hepatopancreatobiliary (HPB) multidisciplinary team. 💡 The best chance of cure is with complete surgical resection in early-stage disease.

📖 About

• Gallbladder cancer is rare in the UK and accounts for less than 1% of new cancers.
• It is more common in older adults and occurs more often in women.
• Most tumours are detected late because symptoms are often non-specific or mimic benign biliary disease.
• It may also be found incidentally after cholecystectomy.

⚠️ Risk Factors

• Gallstones and longstanding biliary inflammation.
• Chronic cholecystitis.
• Gallbladder polyps, especially if large, enlarging, or otherwise suspicious.
• Anomalous pancreaticobiliary duct junction and other congenital biliary abnormalities.
• Older age and female sex.
• Higher background incidence in some populations, including parts of South America and South Asia.

🔬 Pathology

• Most gallbladder cancers are adenocarcinomas.
• They may be infiltrative, mass-forming, or present as irregular wall thickening.
• Direct spread commonly involves the liver, bile ducts, and nearby structures.
• Lymphatic spread is usually to cystic duct, pericholedochal, and portal nodes.
• Advanced disease may spread to the peritoneum or distant sites.

🩺 Clinical Presentation

• Right upper quadrant pain or persistent upper abdominal discomfort.
• Weight loss, anorexia, malaise.
• Jaundice if there is biliary obstruction.
• Nausea, vomiting, fever, or cholestatic symptoms such as dark urine and pale stools.
• Some cases are discovered incidentally on imaging or after surgery for presumed benign gallbladder disease.

🔍 Investigations

• Ultrasound: usually first-line imaging; may show a mass, irregular wall thickening, or suspicious polypoid lesion.
• CT and/or MRI/MRCP: used for staging and to assess local invasion, liver involvement, and biliary anatomy.
• ERCP may be used if biliary decompression or stenting is needed.
• Tissue diagnosis may be needed, especially before nonsurgical systemic treatment.
• Blood tests: FBC, LFTs, U&E, clotting, inflammatory markers; tumour markers such as CA 19-9 and CEA are not diagnostic.

🛠️ Management

• Specialist HPB MDT review is essential.
• Surgery is the only potentially curative treatment.
• Very early disease may be adequately treated by cholecystectomy.
• More invasive but still resectable disease may need extended resection in a specialist centre.
• For advanced, unresectable, or metastatic disease, management may include systemic therapy, biliary drainage/stenting, pain control, nutritional support, and palliative care.
• Where appropriate, current NICE-approved systemic options for advanced biliary tract cancer include durvalumab with gemcitabine and cisplatin.

📊 Prognosis

• Overall prognosis is usually poor because many patients present with advanced disease.
• Outcomes are better when disease is found incidentally at an early stage and completely resected.
• Jaundice, nodal disease, liver invasion, and distant metastases are adverse features.

📚 Teaching Commentary

💡 Exam points:
– Think of gallbladder carcinoma in an older patient with RUQ pain + weight loss + jaundice, especially if symptoms are not behaving like simple biliary colic.
– A suspicious or enlarging gallbladder lesion on ultrasound needs cross-sectional imaging + specialist review.
– The classic practical message is: rare, late, aggressive, and often incidental.

🩺 UK/NICE angle:
– In primary care, an upper abdominal mass consistent with an enlarged gallbladder should trigger an urgent ultrasound within 2 weeks.
– Definitive decisions on surgery, staging, and systemic therapy should be made through an HPB MDT.